Baxter finalized its takeover of Hillrom at $156 per share in cash, valuing the equity at nearly $10.5 billion and the deal at roughly $12.5 billion in enterprise value including assumed debt. The connected-care medtech deal closes weeks ahead of its expected timeline.
Baxter International completes its acquisition of Hillrom, paying $156 per share in cash. The deal adds Hillrom’s patient monitoring, smart bed, and respiratory device lines to Baxter’s medical technology portfolio.
Baxter International completed its acquisition of Hillrom, creating a global medtech leader valued at $15 billion. Baxter paid $156 per share in cash; the transaction carried a purchase price of $10.5 billion and an enterprise value of about $12.5 billion.
Baxter International agrees to acquire Hillrom in a cash transaction priced at $156 per share. The deal values Hillrom at approximately $10.5 billion in equity and about $12.4 billion in enterprise value, including assumed debt. Baxter says the acquisition will expand connected care and medical innovation globally.
